The study by Sun et al. in 2021 demonstrated that combining immunotherapy with a CD93 blocker enhances tumor sensitivity to immune checkpoint blocker therapy, improving treatment response in preclinical tumor models [63]. The gene discussed is CD93; the disease is neoplasm.